Canaccord ups TearLab price target to $14

Tweet Canaccord Genuity has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $14 from $10, saying it recently conducted interviews of TearLab users and found high levels of satisfaction from its customers. The stock closed at $9.55 on Wednesday. “As a result, we gained comfort with our near-term assumptions and increased our instrument [...]

Stephens starts TearLab at overweight

Tweet Stephens Inc. has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with an “overweight” rating and an $11 price target, saying the company is attractively positioned with a unique technology that addresses a large unmet need for the diagnosis and management of dry eye disease.   The stock was quoted at $9.46 Thursday afternoon. “We are [...]

Analysts raise TearLab price targets

Tweet Analysts at Canaccord Genuity, Felt & Co., Roth Capital Markets and Craig-Hallum Capital Group raised their price targets on “buy and strong buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) after the company’s first quarter results and systems orders beat consensus estimates. The stock was changing hands at $9.03, up 13%, after touching a 52-week high of $9.16 [...]

TearLab Q1 revenue jumps 486%

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 486% to $2.5-million from $422,000 a year ago, and was up 54% sequentially from $1.6-million in the fourth quarter of 2012.  The company reported an adjusted net loss of $0.11 per share, beating consensus analyst estimates by a cent. A total of 388 orders for TearLab [...]

Feltl analyst highlights Novadaq and TearLab in WSJ interview

Tweet The Wall Street Journal has announced its 2012 “Best On The Street” stock picker rankings, with Feltl analyst, Ben Haynor, coming second in the Medical Equipment & Supplies category. In an interview with the WSJ, Mr. Haynor called Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) his “best call” during 2012 and said TearLab (NASDAQ:TEAR; TSX:TLB) is the [...]

ASCRS 2013: TearLab gets another vote of confidence from prominent ophthalmologist

Tweet In an EyeWorld interview at this weekend’s American Society of Cataract and Refractive Surgery (ASCRS)/American Society of Ophthalmic Administrators (ASOA) Symposium and Congress, ophthalmologist Dr. Christopher Starr discussed new diagnostic tests for ocular surface disease, including TearLab’s (NASDAQ:TEAR; TSX:TLB) osmolarity test for the diagnoses and management of dry eye disease. Dr. Starr is an assistant [...]

TearLab launches free smartphone IR app

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) announced that its smartphone investor relations application is now available for free download through Apple’s App Store. “The TearLab IR app was designed by Innovasium Digital to provide the investment community with direct and real-time mobile access to company news and information,” TearLab CEO Elias Vamvakas said in a statement. “We [...]

Analysts raise TearLab price targets

Tweet Craig-Hallum Capital Group and Feltl & Co. raised their price targets for TearLab (NASDAQ:TEAR; TSX:TLB) after the company reported fourth quarter financial results and a big jump in systems orders for its Osmolarity device to diagnose and monitor dry eye disease. Feltl analyst Ben Haynor, who rates TearLab as a “strong buy,” moved his [...]

TearLab revenue climbed more than three-fold in Q4

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) posted fourth quarter revenue of $1.6-million, up more than three-fold from $499,000 for the same period in 2011, and an increase of 33% from $1.2-million in the third quarter last year. A total of 232 orders for TearLab systems were booked in the fourth quarter, the company said. Of those, 201 were [...]

Craig-Hallum ups TearLab price target to $7

Tweet Craig-Hallum Capital Group has raised its price target for “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $7 from $5.50. “Post a very favorable experience at the American Academy of Ophthalmology (AAO), we see numerous signs of building physician interest and acceptance of the TearLab Osmolarity System,” writes analyst Stephen Crowley. “In fact, we believe the company’s [...]

Next Page »